{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:04:26Z","timestamp":1790521466002,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"EU-EFPIA Innovative Medicine Initiative (IMI)","award":["115336-2"],"award-info":[{"award-number":["115336-2"]}]},{"name":"KU Leuven Drug Delivery and Disposition Lab"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.tiv.2016.03.008","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T11:02:49Z","timestamp":1459681369000},"page":"179-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes"],"prefix":"10.1016","volume":"34","author":[{"given":"Marlies","family":"Oorts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Baze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bachellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Heyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-7351","authenticated-orcid":false,"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2016.03.008_bb0010","doi-asserted-by":"crossref","DOI":"10.1111\/j.1527-3466.2007.00006.x","article-title":"Perhexiline","author":"Ashrafian","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.tiv.2016.03.008_bb0015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.20961","article-title":"OST\u03b1-OST\u03b2: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia","volume":"42","author":"Ballatori","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.tiv.2016.03.008_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0041-008X(03)00368-5","article-title":"Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity","author":"Boelsterli","year":"2003","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0025","doi-asserted-by":"crossref","DOI":"10.1055\/s-2002-30099","article-title":"Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions","author":"Bohan","year":"2002","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tiv.2016.03.008_bb0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy","volume":"4","author":"Borges","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"issue":"50","key":"10.1016\/j.tiv.2016.03.008_bb0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1331\/JAPhA.2010.08090","article-title":"Clarifying metformin's role and risks in liver dysfunction","volume":"2003","author":"Brackett","year":"2010","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.tiv.2016.03.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2013.07.005","article-title":"Acetaminophen-related hepatotoxicity","author":"Bunchorntavakul","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.tiv.2016.03.008_bb0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tiv.2013.10.020","article-title":"Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates. Toxicol","volume":"28","author":"Chatterjee","year":"2014","journal-title":"In Vitro"},{"key":"10.1016\/j.tiv.2016.03.008_bb0050","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.taap.2013.10.032","article-title":"Hepatocyte-based in vitro model for assessment of drug-induced cholestasis","volume":"274","author":"Chatterjee","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/hep.20567","article-title":"Troglitazone and liver injury: in search of answers","author":"Chojkier","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.tiv.2016.03.008_bb0060","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/dmd.111.040758","article-title":"In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans","volume":"40","author":"Dawson","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.03.008_bb0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/17425255.2013.773973","article-title":"Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity","volume":"9","author":"De Bruyn","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0070","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11202270-000000000-00000","article-title":"Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension","volume":"9","author":"Dhillon","year":"2009","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.tiv.2016.03.008_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2010.03.015","article-title":"Bile salts and cholestasis","author":"Maillette de BuyWenniger","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.tiv.2016.03.008_bb0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.drudis.2007.07.013","article-title":"The significance of mitochondrial toxicity testing in drug development","volume":"12","author":"Dykens","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tiv.2016.03.008_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/toxsci\/kfn056","article-title":"In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone","volume":"103","author":"Dykens","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tiv.2016.03.008_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0009-8981(96)06305-X","article-title":"Hepatic levels of bile acids in end-stage chronic cholestatic liver disease","volume":"251","author":"Fischer","year":"1996","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.tiv.2016.03.008_bb0100","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/mds.10342","article-title":"Entacapone-induced hepatotoxicity and hepatic dysfunction","volume":"17","author":"Fisher","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tiv.2016.03.008_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/j.1875-9114.1989.tb04102.x","article-title":"Hepatotoxicity associated with amiodarone therapy.","author":"Flaharty","year":"1989","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tiv.2016.03.008_bb0110","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/pds.1804","article-title":"Case series of liver failure associated with rosiglitazone and pioglitazone","volume":"18","author":"Floyd","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.tiv.2016.03.008_bb0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.beha.2004.03.005","article-title":"Ximelagatran: a new oral anticoagulant","volume":"17","author":"Francis","year":"2004","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0163-7258(95)00012-6","article-title":"Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity","volume":"67","author":"Fromenty","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tiv.2016.03.008_bb0125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/mol.113.086967","article-title":"Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4\/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity","volume":"84","author":"Fukuda","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-483X(01)00460-7","article-title":"Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt","volume":"167","author":"Funk","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.tiv.2016.03.008_bb0135","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.3748\/wjg.15.3134","article-title":"Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease","volume":"15","author":"Gnewuch","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0140","series-title":"Drug-induced Liver Disease","author":"Kaplowitz","year":"2013"},{"key":"10.1016\/j.tiv.2016.03.008_bb0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-3-642-00663-0_13","article-title":"Drug-induced liver injury in humans: the case of ximelagatran","volume":"196","author":"Keisu","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/jpet.114.220491","article-title":"Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists","volume":"352","author":"Kenna","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tiv.2016.03.008_bb0155","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.tiv.2007.11.014","article-title":"Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol","volume":"22","author":"Kenne","year":"2008","journal-title":"In Vitro"},{"key":"10.1016\/j.tiv.2016.03.008_bb0160","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.tiv.2011.11.002","article-title":"BSEP inhibition: in vitro screens to assess cholestatic potential of drugs. Toxicol","volume":"26","author":"Kis","year":"2012","journal-title":"In Vitro"},{"key":"10.1016\/j.tiv.2016.03.008_bb0165","first-page":"192","article-title":"Histopathologic changes associated with fialuridine hepatotoxicity","volume":"10","author":"Kleiner","year":"1997","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0170","article-title":"Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters MRP3 and MRP4","author":"Kock","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2016.03.008_bb0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/toxsci\/kfj095","article-title":"Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone","volume":"90","author":"Kostrubsky","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0180","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clinre.2012.06.006","article-title":"The bile salt export pump (BSEP) in health and disease","volume":"36","author":"Kubitz","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2007.06.006","article-title":"Acetaminophen hepatotoxicity","author":"Larson","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.tiv.2016.03.008_bb0190","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/diacare.25.5.815","article-title":"Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction","volume":"25","author":"Lebovitz","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tiv.2016.03.008_bb0195","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tiv.2016.03.008_bb0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.tiv.2016.03.008_bb0205","series-title":"Review of the Fialuridine (FIAU) Clinical Trials","author":"Manning","year":"1995"},{"key":"10.1016\/j.tiv.2016.03.008_bb0210","doi-asserted-by":"crossref","DOI":"10.1021\/mp0700357","article-title":"Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity","author":"Marion","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.tiv.2016.03.008_bb0215","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1172\/JCI59755","article-title":"The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation","volume":"122","author":"McGill","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tiv.2016.03.008_bb0220","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199510263331702","article-title":"Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B","author":"McKenzie","year":"1995","journal-title":"New England J. Med."},{"key":"10.1016\/j.tiv.2016.03.008_bb0225","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.2337\/dc11-2306","article-title":"Metformin-induced hepatotoxicity","volume":"35","author":"Miralles-Linares","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tiv.2016.03.008_bb0230","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","article-title":"Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development","volume":"118","author":"Morgan","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0235","doi-asserted-by":"crossref","DOI":"10.1001\/archneur.57.2.263","article-title":"Tolcapone and hepatotoxic effects. Tasmar Advisory Panel.","author":"Olanow","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0240","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.vascn.2015.03.002","article-title":"Drug-induced cholestasis detection in cryopreserved rat hepatocytes in sandwich culture","volume":"73","author":"Oorts","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tiv.2016.03.008_bb0245","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/hep.24229","article-title":"Drug-induced cholestasis","volume":"53","author":"Padda","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.tiv.2016.03.008_bb0250","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.21359","article-title":"Hepatobiliary transporters and drug-induced cholestasis","volume":"44","author":"Pauli-Magnus","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.tiv.2016.03.008_bb0255","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/toxsci\/kft197","article-title":"Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP\/ABCB11)","volume":"136","author":"Pedersen","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0260","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0265","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s11095-007-9289-1","article-title":"Bile acid transporters: structure, function, regulation and pathophysiological implications","volume":"24","author":"Alrefai","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tiv.2016.03.008_bb0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002280050657","article-title":"Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition","volume":"55","author":"Rouru","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0275","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1016\/j.jchromb.2009.09.038","article-title":"Rapid quantification of bile acids and their conjugates in serum by liquid chromatography\u2013tandem mass spectrometry","volume":"877","author":"Scherer","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0280","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.tiv.2009.07.019","article-title":"Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol","volume":"23","author":"Sergent","year":"2009","journal-title":"In Vitro"},{"key":"10.1016\/j.tiv.2016.03.008_bb0285","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx034033e","article-title":"Mechanisms of troglitazone hepatotoxicity","volume":"16","author":"Smith","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cld.2013.07.009","article-title":"Nonsteroidal anti-inflammatory drug-induced hepatoxicity","author":"Unzueta","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.tiv.2016.03.008_bb0295","article-title":"Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro","author":"Van den Hof","year":"2014","journal-title":"BMC Syst. Biol. Submitted."},{"key":"10.1016\/j.tiv.2016.03.008_bb0300","first-page":"S51","article-title":"COMT inhibitors and liver toxicity","volume":"55","author":"Watkins","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.tiv.2016.03.008_bb0305","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jchromb.2009.11.019","article-title":"High performance liquid chromatography\u2013tandem mass spectrometry for the determination of bile acid concentrations in human plasma","volume":"878","author":"Xiang","year":"2010","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0310","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/kfn109","article-title":"Cellular imaging predictions of clinical drug-induced liver injury","volume":"105","author":"Xu","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001628","article-title":"fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing","volume":"11","author":"Xu","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.tiv.2016.03.008_bb0320","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.taap.2013.01.018","article-title":"Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats","volume":"268","author":"Yamazaki","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0325","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/jps.23584","article-title":"An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters","volume":"102","author":"Yang","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.tiv.2016.03.008_bb0330","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/bjp.2008.267","article-title":"Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model","volume":"154","author":"Yao","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tiv.2016.03.008_bb0335","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1194\/jlr.M300377-JLR200","article-title":"Selective sterol accumulation in ABCG5\/ABCG8-deficient mice","volume":"45","author":"Yu","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.tiv.2016.03.008_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2011.12.018","article-title":"Compilation of 222 drugs' plasma protein binding data and guidance for study designs","author":"Zhang","year":"2012","journal-title":"Drug Discov. Today"}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233316300467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233316300467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T15:44:56Z","timestamp":1545407096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233316300467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":67,"alternative-id":["S0887233316300467"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2016.03.008","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2016.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}